"Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease: a systematic review, meta-a
Selective D1/D5 dopamine receptor partial agonists are proposed to provide motor benefit without the impulse control disorders and somnolence associated with D2/D3 dopamine agonists. With tavapadon under regulatory review, no quantitative synthesis of this drug class exists. Emba
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.